Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exponential Biotherapies has contracted Epistem Holdings to provide specialized preclinical efficacy testing services for agents likely to protect the gastrointestinal tract against radiation damage.
Subscribe to our email newsletter
The first compound that Epistem will assess is Exponential Biotherapies’s (EBI’s) lead candidate drug, EA-230, which is a small peptide immunoregulator that has shown the potential to treat (minimize) radiation insult and could therefore be administered following a terrorist nuclear attack to reduce the level of intestinal related radiation sickness.
Zsolt Harsanyi, chairman and CEO of Exponential Biotherapies, said: “Epistem’s well established assays and unrivalled expertise in the field of gastrointestinal epithelial radiation toxicity are extremely valuable to us in confirming the potential of EA-230 as a therapeutic treatment for radionuclear attack.”